Efficacy of Adipose Tissue Derived Stem Cells for the Treatment of Diabetic Foot Ulcers

Diabetes Mellitus Clinical Trial

Official title:

Autologous Adipose Tissue Derived Stromal Vascular Fraction Versus Cultured Adipose Derived Stem Cells for the Treatment of Chronic Diabetic Wounds

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05610865
• Other study ID #: CEMB-SC02
• Status: Recruiting
• Phase: Phase 1
• Start date: November 20, 2020
• Est. completion date: December 2023

Study information

• Verified date: November 2022
• Source: University of the Punjab
• Contact: Azra Mehmood, PhD
• Phone: +92-333-4107008
• Email: azra_mehmood[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the therapeutic efficacy of uncultured adipose derived stromal vascular fraction (SVF) and cultured adipose derived stem cells (ASCs) both supplemented with platelet rich plasma (PRP) to treat chronic diabetic foot ulcers. It will increase the pragmatic potential of both types of cells as PRP is rich in survival and chemotactic factors. Moreover, the autologous nature of the proposed study will ensure safety of its use in diabetic patients and will unveil the more effective therapeutic option for treatment of foot ulcer wounds.

Description:

Under local or general anesthesia, autologous fat will be harvested by using a manual aspiration or syringe-assisted technique. SVF and ASCs isolation from autologous lipoaspirates will be done by enzymatic digestion method (collagenase Type-1 solution for 45 minutes at 37°C). Cell quality assessment will be done prior to transplantation by trypan blue exclusion assay and total populations and fractions of cells identified by immunocytochemistry / flow cytometry. PRP will be derived by centrifugation from 50-100ml blood collected in anticoagulant carrying bag, from patient at the day of transplantation. The injection volume will depend on the wound area of each patient. 2 million cells/ 0.5 ml PRP will be mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 28
• Est. completion date: December 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 60 Years

Eligibility

Inclusion Criteria:

• Type 1 or Type 2 Diabetes Mellitus

• Age 20-60 years (Male/Female)

• Body mass index 20-30 kg/m2

• Suitable for liposuction

• Condition or Disease: Diabetic Neuropathy

• Wound Type: Chronic foot ulcer

• Approx. wound area: 2 cm2 - 8 cm2

• Wound Condition should be of Wagner's grade I (Limited to soft tissue)

• Duration of wound persistence: 6-24 Weeks

• Transcutaneous oxygen pressure > 30 mmHg, and an ankle brachial pressure index > 0.5.

• Already following an adequate off-loading method

• Provided signed informed consent

Exclusion Criteria:

• Uncontrolled hyperglycemia (HbAlc > 9%)

• Presence of severe clinical sign of infection

• Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors.

• Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases

• Patients with critical limb ischemia and osteomylitis

• Withdrawal of informed consent

Related Conditions & MeSH terms

• Chronic Diabetic Foot Ulcer of Right Foot
• Diabetes Complications
• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Diabetes Mellitus, Type 2
• Diabetic Foot
• Diabetic Foot Infection
• Diabetic Foot Ulcer
• Diabetic Foot Ulcer Neuropathic
• Foot Ulcer
• Ulcer

Intervention

Other:
• Control; Standard-of-care management
Patients will undergo conventional wound care management.

Biological:
• Only PRP injection
Only PRP injected / cm2 intradermally at the border zone & inside of wound surface bed.
• PRP + SVF injection
Uncultured cells (SVF) along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.
• PRP + ASCs injection
Cultured ASCs along PRP were mixed, transferred to 1 cc syringes and injected / cm2 intradermally at the border zone & inside of wound surface bed.

Locations

Country	Name	City	State
Pakistan	Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&RSC)	Lahore	Punjab

Sponsors (4)

Lead Sponsor	Collaborator
University of the Punjab	Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Higher Education Commission (Pakistan), Jinnah Burn and Reconstructive Surgery Centre, Lahore

Country where clinical trial is conducted

Pakistan, 

References & Publications (10)

Álvaro-Afonso FJ, Sanz-Corbalán I, Lázaro-Martínez JL, Kakagia D, Papanas N. Adipose-Derived Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Review of Preclinical and Clinical Studies. Angiology. 2020 Oct;71(9):853-863. doi: 10.1177/0003319720939467. Epub 2020 Jul 29. Review. — View Citation

Carstens MH, Quintana FJ, Calderwood ST, Sevilla JP, Ríos AB, Rivera CM, Calero DW, Zelaya ML, Garcia N, Bertram KA, Rigdon J, Dos-Anjos S, Correa D. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Transl Med. 2021 Aug;10(8):1138-1147. doi: 10.1002/sctm.20-0497. Epub 2021 Apr 7. — View Citation

Didangelos T, Koliakos G, Kouzi K, Arsos G, Kotzampassi K, Tziomalos K, Karamanos D, Hatzitolios AI. Accelerated healing of a diabetic foot ulcer using autologous stromal vascular fraction suspended in platelet-rich plasma. Regen Med. 2018 Apr;13(3):277-281. doi: 10.2217/rme-2017-0069. Epub 2018 May 1. — View Citation

Han SK, Kim HR, Kim WK. The treatment of diabetic foot ulcers with uncultured, processed lipoaspirate cells: a pilot study. Wound Repair Regen. 2010 Jul-Aug;18(4):342-8. doi: 10.1111/j.1524-475X.2010.00593.x. Epub 2010 May 11. — View Citation

Khan A, Junaid N. Prevalence of diabetic foot syndrome amongst population with type 2 diabetes in Pakistan in primary care settings. J Pak Med Assoc. 2017 Dec;67(12):1818-1824. — View Citation

Nolan GS, Smith OJ, Heavey S, Jell G, Mosahebi A. Histological analysis of fat grafting with platelet-rich plasma for diabetic foot ulcers-A randomised controlled trial. Int Wound J. 2022 Feb;19(2):389-398. doi: 10.1111/iwj.13640. Epub 2021 Jun 24. — View Citation

Prakasam N, Prabakar MS, Reshma S, Loganathan K, Senguttuvan K. A clinical study of platelet rich plasma versus conventional dressing in management of diabetic foot ulcers. International Surgery Journal. 2018 Sep 25;5(10):3210-6.

Qin HL, Zhu XH, Zhang B, Zhou L, Wang WY. Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot. Exp Clin Endocrinol Diabetes. 2016 Sep;124(8):497-503. Epub 2016 May 24. — View Citation

Shao S, Pan R, Chen Y. Autologous Platelet-Rich Plasma for Diabetic Foot Ulcer. Trends Endocrinol Metab. 2020 Dec;31(12):885-890. doi: 10.1016/j.tem.2020.10.003. Epub 2020 Nov 13. — View Citation

Yin S, Yang X, Bi H, Zhao Z. Combined Use of Autologous Stromal Vascular Fraction Cells and Platelet-Rich Plasma for Chronic Ulceration of the Diabetic Lower Limb Improves Wound Healing. Int J Low Extrem Wounds. 2021 Jun;20(2):135-142. doi: 10.1177/1534734620907978. Epub 2020 Mar 4. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Interview and visual inspection of ulcers recovery rate	This will be done in terms of diameter (cm2) of wounds, monitored in both cell transplanted and standard care patients after week interval till 3 months.	3 months
Secondary	Percentages (%) of wound closure rate (with respect to time) will be assessed.	Change in wound size (cm2) will be determined	3 months